148 related articles for article (PubMed ID: 32347114)
21. Dermatological side effects of brimonidine: a report of three cases.
Sodhi PK; Verma L; Ratan J
J Dermatol; 2003 Sep; 30(9):697-700. PubMed ID: 14578562
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, safety, and current applications of brimonidine.
Fudemberg SJ; Batiste C; Katz LJ
Expert Opin Drug Saf; 2008 Nov; 7(6):795-9. PubMed ID: 18983225
[TBL] [Abstract][Full Text] [Related]
23. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
Goñi FJ;
Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
[TBL] [Abstract][Full Text] [Related]
24. Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans.
Takamura Y; Tomomatsu T; Matsumura T; Takihara Y; Kozai S; Arimura S; Yokota S; Inatani M
J Ocul Pharmacol Ther; 2015 Jun; 31(5):282-5. PubMed ID: 25918904
[TBL] [Abstract][Full Text] [Related]
25. Preservative-free
Duru Z; Ozsaygili C
Cutan Ocul Toxicol; 2020 Mar; 39(1):21-24. PubMed ID: 31615279
[No Abstract] [Full Text] [Related]
26. Brimonidine tartrate for the treatment of glaucoma.
Oh DJ; Chen JL; Vajaranant TS; Dikopf MS
Expert Opin Pharmacother; 2019 Jan; 20(1):115-122. PubMed ID: 30407890
[TBL] [Abstract][Full Text] [Related]
27. Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema.
Cookson H; McFadden J; White J; White IR
Contact Dermatitis; 2015 Dec; 73(6):366-7. PubMed ID: 26768997
[No Abstract] [Full Text] [Related]
28. Corneal sterile infiltration induced by topical use of ocular hypotensive agent.
Manabe Y; Sawada A; Mochizuki K
Eur J Ophthalmol; 2020 Sep; 30(5):NP23-NP25. PubMed ID: 31096781
[TBL] [Abstract][Full Text] [Related]
29. Anterior uveitis as a side effect of topical brimonidine.
Byles DB; Frith P; Salmon JF
Am J Ophthalmol; 2000 Sep; 130(3):287-91. PubMed ID: 11020406
[TBL] [Abstract][Full Text] [Related]
30. Brimonidine Induced Anterior Uveitis.
Beltz J; Zamir E
Ocul Immunol Inflamm; 2016; 24(2):128-33. PubMed ID: 26399160
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5% timolol in normal-tension glaucoma patients.
Kim JM; Kim TW; Kim CY; Kim HK; Park KH
Jpn J Ophthalmol; 2016 Jan; 60(1):20-6. PubMed ID: 26578422
[TBL] [Abstract][Full Text] [Related]
32. A case of bilateral deep stromal corneal opacity and vascularization after use of multiple antiglaucoma medications including brimonidine tartrate ophthalmic solution.
Tsujinaka A; Takai Y; Inoue Y; Tanito M
Acta Ophthalmol; 2019 Sep; 97(6):e948-e949. PubMed ID: 30609169
[No Abstract] [Full Text] [Related]
33. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents.
Maus TL; Nau C; Brubaker RF
Arch Ophthalmol; 1999 May; 117(5):586-91. PubMed ID: 10326954
[TBL] [Abstract][Full Text] [Related]
34. [Hypotensive effect of three different formulations of brimonidine tartrate in normal eyes].
Abud TB; Scuoteguazza Filho M; Oliveira ES; Abud JF; Prata Junior JA
Arq Bras Oftalmol; 2013; 76(2):69-71. PubMed ID: 23828464
[TBL] [Abstract][Full Text] [Related]
35. Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial.
Felfeli T; Hostovsky A; Trussart R; Yan P; Brent MH; Mandelcorn ED
Br J Ophthalmol; 2019 Oct; 103(10):1388-1394. PubMed ID: 30573499
[TBL] [Abstract][Full Text] [Related]
36. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
[TBL] [Abstract][Full Text] [Related]
37. Adverse effects of brimonidine eye drop in children: A case series.
Ghaffari Z; Zakariaei Z; Ghazaeian M; Jafari R; Ezoddin N; Yousefi Nouraee H; Navaeifar MR
J Clin Pharm Ther; 2021 Oct; 46(5):1469-1472. PubMed ID: 33626597
[TBL] [Abstract][Full Text] [Related]
38. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial.
Wilhelm B; Lüdtke H; Wilhelm H;
Graefes Arch Clin Exp Ophthalmol; 2006 May; 244(5):551-8. PubMed ID: 16151785
[TBL] [Abstract][Full Text] [Related]
40. Allergic contact dermatitis to topical brimonidine.
Rajagopalan A; Rajagopalan B
Australas J Dermatol; 2015 Aug; 56(3):235. PubMed ID: 26201375
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
